hepatic encephalopathy

News

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed two phase 3 trials.

News

Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.